A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.
AstraZeneca AB Prioritizes Chronic Disease Management and Healthcare Innovation with Asthma Control Initiatives and Monoclonal Antibody Research
Published:
April 26, 2024
by Industry Intelligence Inc.
|
AstraZeneca AB Catalyzes Industry Growth with Andean Innovation Center Launch and Advocates for Male Breast Cancer Awareness, While Addressing Heart Failure Challenges in the Netherlands
Published:
April 25, 2024
by Industry Intelligence Inc.
|
Executive Perspective: AstraZeneca CEO Pascal Soriot defends recent spate of acquisitions, arguing they're vital for future growth; Soriot says the deals aim to create synergy between oncology, vaccines, and respiratory disease products
Published:
April 25, 2024
by FiercePharma
|
AstraZeneca reports Q1 revenue up 17% year-over-year to US$12.7B, operating profit up 22% to US$3.1B, with oncology sales growing 23% YoY to US$5.1B, metabolic and cardiovascular drug sales increasing 20% YoY to US$3.1B; annual guidance remains unchanged
Published:
April 25, 2024
by BioPharma Dive
|
Astrazeneca reports Q1 2024 results
Published:
April 25, 2024
by AstraZeneca AB
|
Ask us about our Bioeconomy market view